Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
  • Investors
  • Careers
background

Scientific Presentations

The information included below was provided in connection with a presentation or publication on the date indicated and is qualified as such. Revolution Medicines disclaims any duty to update these materials.

 

 

Publication / Presentation

April 18, 2023

Bi-steric mTORC1 inhibitors are superior to rapamycin and induce apoptotic cell death in tumor models with hyperactivated mTORC1

Read more

Publication / Presentation

April 17, 2023

Preclinical evaluation of RM-042, an orally bioavailable inhibitor of GTP-RAS, in models of pancreatic ductal adenocarcinoma

Read more

Publication / Presentation

April 17, 2023

RMC-9805, a First-in-Class, Mutant-Selective, Covalent and Orally Bioavailable KRASG12D(ON) Inhibitor, Promotes Cancer-Associated Neoantigen Recognition and Synergizes with Immunotherapy in Preclinical Models

Read more

Publication / Presentation

April 17, 2023

RMC-0708 (RM-046), a first-in-class, mutant-selective and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target

Read more

Publication / Presentation

April 16, 2023

Discovery of RMC-6291, a tri-complex KRASG12C(ON) inhibitor

Read more
VIEW ALL
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us